<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02282514</url>
  </required_header>
  <id_info>
    <org_study_id>DIAD.SPS.2014</org_study_id>
    <nct_id>NCT02282514</nct_id>
  </id_info>
  <brief_title>Stem Cell Transplantation for Stiff Person Syndrome (SPS)</brief_title>
  <acronym>SPS</acronym>
  <official_title>Non-myeloablative Hematopoietic Stem Cell Transplantation for Stiff Person Syndrome (SPS) and Anti-GAD Antibody Variants: Progressive Encephalomyelitis With Rigidity and Myoclonus (PERM), and Adult Onset Autoimmune Anti-GAD Positive Cerebellar Ataxia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Northwestern University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Non-myeloablative regimens (as the investigators use herein) are designed to maximally&#xD;
      suppress the immune system without destruction of the bone marrow stem cell compartment.&#xD;
&#xD;
      When using a non-myeloablative regimen recovery occurs without infusion of stem cells and the&#xD;
      stem cells are autologous. While not necessary for recovery, stem cell infusion may shorten&#xD;
      the interval of neutropenia and attendant complications. Thus in reality there is no&#xD;
      transplant only an autologous supportive blood product.&#xD;
&#xD;
      Based on our encouraging results of non-myeloablative hematopoietic stem cell&#xD;
      transplantation, for patients with multiple sclerosis and chronic inflammatory demyelinating&#xD;
      polyneuropathy, the investigators will investigate the role of non-myeloablative&#xD;
      hematopoietic stem cell transplantation for patients with SPS who require assistance to&#xD;
      ambulate.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pre-study Testing&#xD;
&#xD;
        1. History and physical&#xD;
&#xD;
        2. Electrocardiogram (EKG)&#xD;
&#xD;
        3. Dobutamine stress echocardiogram&#xD;
&#xD;
        4. High-resolution computed tomography of the chest (HRCT)&#xD;
&#xD;
        5. Blood draw for laboratory tests- these tests will include a complete blood count,&#xD;
           evaluating liver and kidney function, assessing immune system, tissue typing, and&#xD;
           checking for certain germs that can cause infections, including a pregnancy test for&#xD;
           females and prostate-specific antigen (PSA) for male as well as testing for HIV&#xD;
&#xD;
        6. Pulmonary Function Test (PFT)&#xD;
&#xD;
        7. Electromyography (EMG)&#xD;
&#xD;
        8. Magnetic Resonance Imaging (MRI) of the Abdomen and Pelvis&#xD;
&#xD;
        9. Magnetic Resonance Imaging (MRI) of the Spinal Cord&#xD;
&#xD;
       10. Magnetic Resonance Imaging (MRI) of the Brain with Gadolinium (only if PERM of&#xD;
           cerebellar ataxia)&#xD;
&#xD;
       11. Colonoscopy&#xD;
&#xD;
       12. Mammogram (if female)&#xD;
&#xD;
       13. Timed ambulation&#xD;
&#xD;
       14. Quality of Life Questionnaires [ Short Form (36) Health Survey (SF36) and Barthel Index]&#xD;
&#xD;
       15. Chronic Pain Acceptance Questionnaire (CPAQ)&#xD;
&#xD;
       16. Rankin Functional Scale&#xD;
&#xD;
       17. Modified Ashworth Scale&#xD;
&#xD;
       18. Purkinje Cell Cytoplasmic Antibody, Type 1 (PCA-1), Purkinje Cell Cytoplasmic Antibody,&#xD;
           Type 2 (PCA-2) antibody (only if cerebellar ataxia)&#xD;
&#xD;
       19. Spinocerebellar ataxia (SCA) 1, 2, 3, 4, 5, 6, 7, 8 genes (only if ataxia)&#xD;
&#xD;
      Study Treatment&#xD;
&#xD;
      Stem Cell Collection: Cyclophosphamide 2.0 gm/m2 will be given on day 0, G-CSF 5-10&#xD;
      mcg/kg/day subcutaneous (SQ) will start on day +5 and will continue until apheresis is&#xD;
      discontinued. Apheresis will begin when the absolute neutrophil count (ANC) &gt; 1.0 x 109/L and&#xD;
      continue until &gt;2.0 x 106 cluster of differentiation 34 (CD34)+ cells/kg patient weight are&#xD;
      cryopreserved. A 10-15 liter apheresis will be performed unless stopped earlier for clinical&#xD;
      judgment of toxicity (e.g., numbness, tetany). A maximum of four apheresis will be performed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Could not predict who would respond, relapse or go into remission&#xD;
  </why_stopped>
  <start_date>October 2014</start_date>
  <completion_date type="Actual">August 30, 2019</completion_date>
  <primary_completion_date type="Actual">August 19, 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Mean 3.6 years</time_frame>
    <description>Number of Participants who Did Not Experience Treatment-Related Mortality</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reduction of Muscle Relaxation Anti-spasmatic Medications</measure>
    <time_frame>Mean 3.6 years</time_frame>
    <description>Decrease (50%) and complete discontinuation of muscle relaxation anti-spasmatic medications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short-form 36 Quality of Life Questionnaire (SF-36 QOL)</measure>
    <time_frame>mean 3.6 years</time_frame>
    <description>Improvement is defined as a statistically significant change in SF-36 QOL score. The scale is 0-100. The lower the score the worse quality of life.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Stiff-Person Syndrome</condition>
  <arm_group>
    <arm_group_label>Hematopoietic Stem Cell Transplantation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The conditioning regimen will be 200 mg/kg of intravenous cyclophosphamide given in 4 equal fractions on days -5 through -2 with intravenous mesna. Rabbit antithymocyte globulin (rATG) (ThymoglobulinÂ®) will be dosed at 0.5 mg/kg on day-5, 1.0 mg/kg on days -4 and -3, and then 1.5 mg/kg on days -2 and -1. Methylprednisolone 1000 mg will be infused intravenously before each dose of rATG. Autologous hematopoietic stem cells will be infused intravenously on day 0. A granulocyte-colony stimulating factor (G-CSF) 5-10 mcg/kg will be started on day + 5 and continued until neutrophil engraftment. Intravenous Rituxan (500mg) will be administered on days -6 and +1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Autologous Hematopoietic Stem Cells</intervention_name>
    <description>The stem cells will be collected from patient's blood during mobilization. Then the patient will be given high dose chemotherapy in accordance with approved recommendations for use in conditioning regimens for stem cell transplant in autoimmune diseases. Autologous Hematopoietic Stem Cell Transplantation is to re-infuse immature cells that can re-establish blood production and patient's immune system.</description>
    <arm_group_label>Hematopoietic Stem Cell Transplantation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>An alkylating agent which causes prevention of cell division by forming adducts with DNA</description>
    <arm_group_label>Hematopoietic Stem Cell Transplantation</arm_group_label>
    <other_name>Cytoxan</other_name>
    <other_name>Neosar</other_name>
    <other_name>Endoxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mesna</intervention_name>
    <description>Medication used to decrease the risk of hemorrhagic cystitis prophylaxis</description>
    <arm_group_label>Hematopoietic Stem Cell Transplantation</arm_group_label>
    <other_name>Mesnex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rATG</intervention_name>
    <description>A predominantly lymphocyte-specific immunosuppressive agent which contains antibodies specific to the antigens commonly found on the surface of T cells</description>
    <arm_group_label>Hematopoietic Stem Cell Transplantation</arm_group_label>
    <other_name>Thymoglobulin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylprednisolone</intervention_name>
    <description>Steroid</description>
    <arm_group_label>Hematopoietic Stem Cell Transplantation</arm_group_label>
    <other_name>Solu-Medrol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>G-CSF</intervention_name>
    <description>Granulocyte-colony stimulating factor; a glycoprotein that stimulates the bone marrow to produce granulocytes and stem cells and release them into the bloodstream</description>
    <arm_group_label>Hematopoietic Stem Cell Transplantation</arm_group_label>
    <other_name>Neupogen</other_name>
    <other_name>Filgrastim</other_name>
    <other_name>Granix</other_name>
    <other_name>Zarxio</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituxan</intervention_name>
    <description>A chimeric monoclonal antibody used in the treatment of B cell non-Hodgkin's lymphoma, B cell leukemia, and some autoimmune disorders</description>
    <arm_group_label>Hematopoietic Stem Cell Transplantation</arm_group_label>
    <other_name>Rituximab</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Diagnosis of Stiff-person Syndrome and&#xD;
&#xD;
               -  Age between 18 and 60 years old&#xD;
&#xD;
               -  Failure of medically tolerable doses (20-40 mg/day) of diazepam&#xD;
&#xD;
               -  Failure of either intravenous immunoglobulin (IVIg) and or plasmapheresis&#xD;
&#xD;
               -  Stiffness in the axial muscles, prominently in the abdominal and thoracolumbar&#xD;
                  paraspinal muscle leading to a fixed deformity (hyperlordosis)&#xD;
&#xD;
               -  Superimposed painful spasms precipitated by unexpected noises, emotional stress,&#xD;
                  tactile stimuli&#xD;
&#xD;
               -  Confirmation of the continuous motor unit activity in agonist and antagonist&#xD;
                  muscles by electromyography when off diazepam and anti-spasmatic medications&#xD;
&#xD;
               -  Absence of neurological or cognitive impairments that could explain the stiffness&#xD;
&#xD;
               -  Inability to run or walk, or abnormal gait&#xD;
&#xD;
          2. Diagnosis of a SPS variant- Progressive Encephalomyelitis with Rigidity and Myoclonus&#xD;
             (PERM) defined as:&#xD;
&#xD;
             Acute onset of painful rigidity and muscle spasms in the limbs and trunk&#xD;
&#xD;
               -  Brainstem dysfunction (nystagmus, opsoclonus, ophthalmoparesis, deafness,&#xD;
                  dysarthria, dysphagia)&#xD;
&#xD;
               -  Profound autonomic disturbance.&#xD;
&#xD;
               -  Positive serology for GAD65 (or amphiphysin) autoantibodies, assessed by&#xD;
                  immunocytochemistry, western blot or radioimmunoassay (&gt;1000 u/ml)&#xD;
&#xD;
               -  MRI may show increased signal intensity throughout the spinal cord and the&#xD;
                  brainstem&#xD;
&#xD;
          3. Diagnosis of a SPS variant - anti-GAD positive cerebellar ataxia&#xD;
&#xD;
               -  Subacute or chronic onset of cerebellar symptoms-gait or limb ataxia, dysarthria,&#xD;
                  nystagmus&#xD;
&#xD;
               -  Positive serology for GAD65 (or amphiphysin) autoantibodies, assessed by&#xD;
                  immunocytochemistry, western blot or radioimmunoassay (&gt;1000 u/ml)&#xD;
&#xD;
               -  Anti-GAD antibody in cerebrospinal fluid&#xD;
&#xD;
               -  Abnormal MRI imaging of brainstem or cerebellum other than cerebellar atrophy&#xD;
&#xD;
               -  Negative history of toxin or alcohol&#xD;
&#xD;
               -  Absence of Vitamin B12 or Vitamin E deficiency&#xD;
&#xD;
               -  Absence of positive HIV, syphilis or whipple disease&#xD;
&#xD;
               -  Absence of consanguinity, positive family history for ataxia or positive genetic&#xD;
                  screen for spinocerebellar ataxia (SCA) 1, SCA 2, SCA 3, SCA 6, SCA 7 or SCA 8&#xD;
                  mutation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current or prior history of a malignancy or paraneoplastic syndrome&#xD;
&#xD;
          -  Inability to sign and understand consent and be compliant with treatment&#xD;
&#xD;
          -  Positive pregnancy test&#xD;
&#xD;
          -  Inability to or comprehend irreversible sterility as a possible side effect&#xD;
&#xD;
          -  Amphiphysin antibody positive&#xD;
&#xD;
          -  Left ventricular ejection fraction (LVEF) &lt; 45% or ischemic coronary artery disease on&#xD;
             dobutamine stress echocardiogram&#xD;
&#xD;
          -  Diffusing capacity of the lungs for carbon monoxide (DLCO) &lt; 60% predicted&#xD;
&#xD;
          -  Serum creatinine &gt; 2.0 mg/dl&#xD;
&#xD;
          -  Bilirubin &gt;2.0 mg/dl&#xD;
&#xD;
          -  Platelet count &lt; 100,000 / ul, white blood cell count (WBC) &lt; 1,500 cells/mm3&#xD;
&#xD;
          -  History of toxin or alcohol abuse&#xD;
&#xD;
          -  History of Vitamin B12 or Vitamin E deficiency&#xD;
&#xD;
          -  Positive HIV, syphilis, or whipple disease&#xD;
&#xD;
          -  Consanguinity, positive family history for ataxia or positive genetic screen for SCA1,&#xD;
             SCA2, SCA3, SCA6, SCA 7 or SCA8 mutation (if ataxia present)&#xD;
&#xD;
          -  Absence of at least one SPS associated antibody such as anti-GAD, or&#xD;
             gamma-aminobutyric acid (GABA)-A receptor associated protein, or synaptophysin, or&#xD;
             gephyrin, or GABA-transaminase&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard Burt, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwestern University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://doi.org/10.1212/WNL.0000000000011338</url>
    <description>Burt RK, et al. Neurology. 2020.</description>
  </link>
  <results_reference>
    <citation>Burt RK, Balabanov R, Han X, Quigley K, Arnautovic I, Helenowski I, Rose J, Siddique T. Autologous Hematopoietic Stem Cell Transplantation for Stiff-Person Spectrum Disorder: A Clinical Trial. Neurology. 2021 Feb 9;96(6):e817-e830. doi: 10.1212/WNL.0000000000011338. Epub 2020 Dec 14.</citation>
    <PMID>33318163</PMID>
  </results_reference>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>October 30, 2014</study_first_submitted>
  <study_first_submitted_qc>October 31, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 4, 2014</study_first_posted>
  <results_first_submitted>November 16, 2020</results_first_submitted>
  <results_first_submitted_qc>December 9, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">January 6, 2021</results_first_posted>
  <last_update_submitted>January 6, 2021</last_update_submitted>
  <last_update_submitted_qc>January 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Northwestern University</investigator_affiliation>
    <investigator_full_name>Richard Burt, MD</investigator_full_name>
    <investigator_title>Professor, Division Chief</investigator_title>
  </responsible_party>
  <keyword>Autoimmune Diseases</keyword>
  <keyword>Autologous Hematopoietic Stem Cell Transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stiff-Person Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Thymoglobulin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 30, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/14/NCT02282514/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Hematopoietic Stem Cell Transplantation</title>
          <description>Conditioning regimen will be 200 mg/kg of IV cyclophosphamide given in 4 equal fractions on days -5 through -2 with IV mesna. Rabbit antithymocyte globulin (rATG) (ThymoglobulinÂ®) will be dosed at 0.5 mg/kg on day-5, 1.0 mg/kg on days -4 and -3, and then 1.5 mg/kg on days -2 and -1. Methylprednisolone 1000 mg will be infused IV before each dose of rATG. Autologous hematopoietic stem cells (HSCT) will be infused IV on day 0. A granulocyte-colony stimulating factor (G-CSF) 5-10 mcg/kg will be started on day + 5 and continued until neutrophil engraftment. Intravenous Rituxan (500mg) will be administered on days -6 and +1.&#xD;
HSCT: cells will be collected from blood during mobilization. Then the patient will be given high dose chemotherapy in accordance with approved recommendations for use in conditioning regimens for stem cell transplant in autoimmune diseases. Autologous HSCT is to re-infuse immature cells that can re-establish blood production and patient's immune system.&#xD;
Cyclophosphamide: Alkylating agent which causes prevention of cell division by forming adducts with DNA Mesna: Medication used to decrease the risk of hemorrhagic cystitis rATG: lymphocyte-specific immunosuppressive agent Methylprednisolone: Steroid G-CSF: Granulocyte-colony stimulating factor; a glycoprotein that stimulates the bone marrow to produce granulocytes and stem cells and release them into the bloodstream Rituxan: Chimeric monoclonal antibody</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Hematopoietic Stem Cell Transplantation</title>
          <description>Conditioning regimen will be 200 mg/kg of IV cyclophosphamide given in 4 equal fractions on days -5 through -2 with IV mesna. Rabbit antithymocyte globulin (rATG) (ThymoglobulinÂ®) will be dosed at 0.5 mg/kg on day-5, 1.0 mg/kg on days -4 and -3, and then 1.5 mg/kg on days -2 and -1. Methylprednisolone 1000 mg will be infused IV before each dose of rATG. Autologous hematopoietic stem cells (HSCT) will be infused IV on day 0. A granulocyte-colony stimulating factor (G-CSF) 5-10 mcg/kg will be started on day + 5 and continued until neutrophil engraftment. Intravenous Rituxan (500mg) will be administered on days -6 and +1.&#xD;
HSCT: cells will be collected from blood during mobilization. Then the patient will be given high dose chemotherapy in accordance with approved recommendations for use in conditioning regimens for stem cell transplant in autoimmune diseases. Autologous HSCT is to re-infuse immature cells that can re-establish blood production and patient's immune system.&#xD;
Cyclophosphamide: Alkylating agent which causes prevention of cell division by forming adducts with DNA Mesna: Medication used to decrease the risk of hemorrhagic cystitis rATG: lymphocyte-specific immunosuppressive agent Methylprednisolone: Steroid G-CSF: Granulocyte-colony stimulating factor; a glycoprotein that stimulates the bone marrow to produce granulocytes and stem cells and release them into the bloodstream Rituxan: Chimeric monoclonal antibody</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="23"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48.3" lower_limit="27" upper_limit="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Survival</title>
        <description>Number of Participants who Did Not Experience Treatment-Related Mortality</description>
        <time_frame>Mean 3.6 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Hematopoietic Stem Cell Transplantation</title>
            <description>Conditioning regimen will be 200 mg/kg of IV cyclophosphamide given in 4 equal fractions on days -5 through -2 with IV mesna. Rabbit antithymocyte globulin (rATG) (ThymoglobulinÂ®) will be dosed at 0.5 mg/kg on day-5, 1.0 mg/kg on days -4 and -3, and then 1.5 mg/kg on days -2 and -1. Methylprednisolone 1000 mg will be infused IV before each dose of rATG. Autologous hematopoietic stem cells (HSCT) will be infused IV on day 0. A granulocyte-colony stimulating factor (G-CSF) 5-10 mcg/kg will be started on day + 5 and continued until neutrophil engraftment. Intravenous Rituxan (500mg) will be administered on days -6 and +1.&#xD;
HSCT: cells will be collected from blood during mobilization. Then the patient will be given high dose chemotherapy in accordance with approved recommendations for use in conditioning regimens for stem cell transplant in autoimmune diseases. Autologous HSCT is to re-infuse immature cells that can re-establish blood production and patient's immune system.&#xD;
Cyclophosphamide: Alkylating agent which causes prevention of cell division by forming adducts with DNA Mesna: Medication used to decrease the risk of hemorrhagic cystitis rATG: lymphocyte-specific immunosuppressive agent Methylprednisolone: Steroid G-CSF: Granulocyte-colony stimulating factor; a glycoprotein that stimulates the bone marrow to produce granulocytes and stem cells and release them into the bloodstream Rituxan: Chimeric monoclonal antibody</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>Number of Participants who Did Not Experience Treatment-Related Mortality</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Reduction of Muscle Relaxation Anti-spasmatic Medications</title>
        <description>Decrease (50%) and complete discontinuation of muscle relaxation anti-spasmatic medications</description>
        <time_frame>Mean 3.6 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Hematopoietic Stem Cell Transplantation</title>
            <description>Conditioning regimen will be 200 mg/kg of IV cyclophosphamide given in 4 equal fractions on days -5 through -2 with IV mesna. Rabbit antithymocyte globulin (rATG) (ThymoglobulinÂ®) will be dosed at 0.5 mg/kg on day-5, 1.0 mg/kg on days -4 and -3, and then 1.5 mg/kg on days -2 and -1. Methylprednisolone 1000 mg will be infused IV before each dose of rATG. Autologous hematopoietic stem cells (HSCT) will be infused IV on day 0. A granulocyte-colony stimulating factor (G-CSF) 5-10 mcg/kg will be started on day + 5 and continued until neutrophil engraftment. Intravenous Rituxan (500mg) will be administered on days -6 and +1.&#xD;
HSCT: cells will be collected from blood during mobilization. Then the patient will be given high dose chemotherapy in accordance with approved recommendations for use in conditioning regimens for stem cell transplant in autoimmune diseases. Autologous HSCT is to re-infuse immature cells that can re-establish blood production and patient's immune system.&#xD;
Cyclophosphamide: Alkylating agent which causes prevention of cell division by forming adducts with DNA Mesna: Medication used to decrease the risk of hemorrhagic cystitis rATG: lymphocyte-specific immunosuppressive agent Methylprednisolone: Steroid G-CSF: Granulocyte-colony stimulating factor; a glycoprotein that stimulates the bone marrow to produce granulocytes and stem cells and release them into the bloodstream Rituxan: Chimeric monoclonal antibody</description>
          </group>
        </group_list>
        <measure>
          <title>Reduction of Muscle Relaxation Anti-spasmatic Medications</title>
          <description>Decrease (50%) and complete discontinuation of muscle relaxation anti-spasmatic medications</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Short-form 36 Quality of Life Questionnaire (SF-36 QOL)</title>
        <description>Improvement is defined as a statistically significant change in SF-36 QOL score. The scale is 0-100. The lower the score the worse quality of life.</description>
        <time_frame>mean 3.6 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Hematopoietic Stem Cell Transplantation</title>
            <description>Conditioning regimen will be 200 mg/kg of IV cyclophosphamide given in 4 equal fractions on days -5 through -2 with IV mesna. Rabbit antithymocyte globulin (rATG) (ThymoglobulinÂ®) will be dosed at 0.5 mg/kg on day-5, 1.0 mg/kg on days -4 and -3, and then 1.5 mg/kg on days -2 and -1. Methylprednisolone 1000 mg will be infused IV before each dose of rATG. Autologous hematopoietic stem cells (HSCT) will be infused IV on day 0. A granulocyte-colony stimulating factor (G-CSF) 5-10 mcg/kg will be started on day + 5 and continued until neutrophil engraftment. Intravenous Rituxan (500mg) will be administered on days -6 and +1.&#xD;
HSCT: cells will be collected from blood during mobilization. Then the patient will be given high dose chemotherapy in accordance with approved recommendations for use in conditioning regimens for stem cell transplant in autoimmune diseases. Autologous HSCT is to re-infuse immature cells that can re-establish blood production and patient's immune system.&#xD;
Cyclophosphamide: Alkylating agent which causes prevention of cell division by forming adducts with DNA Mesna: Medication used to decrease the risk of hemorrhagic cystitis rATG: lymphocyte-specific immunosuppressive agent Methylprednisolone: Steroid G-CSF: Granulocyte-colony stimulating factor; a glycoprotein that stimulates the bone marrow to produce granulocytes and stem cells and release them into the bloodstream Rituxan: Chimeric monoclonal antibody</description>
          </group>
        </group_list>
        <measure>
          <title>Short-form 36 Quality of Life Questionnaire (SF-36 QOL)</title>
          <description>Improvement is defined as a statistically significant change in SF-36 QOL score. The scale is 0-100. The lower the score the worse quality of life.</description>
          <units>units on a scale</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre Treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.75" spread="12.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post Treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.35" spread="22.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 4.5 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Hematopoietic Stem Cell Transplantation</title>
          <description>Conditioning regimen will be 200 mg/kg of IV cyclophosphamide given in 4 equal fractions on days -5 through -2 with IV mesna. Rabbit antithymocyte globulin (rATG) (ThymoglobulinÂ®) will be dosed at 0.5 mg/kg on day-5, 1.0 mg/kg on days -4 and -3, and then 1.5 mg/kg on days -2 and -1. Methylprednisolone 1000 mg will be infused IV before each dose of rATG. Autologous hematopoietic stem cells (HSCT) will be infused IV on day 0. A granulocyte-colony stimulating factor (G-CSF) 5-10 mcg/kg will be started on day + 5 and continued until neutrophil engraftment. Intravenous Rituxan (500mg) will be administered on days -6 and +1.&#xD;
HSCT: cells will be collected from blood during mobilization. Then the patient will be given high dose chemotherapy in accordance with approved recommendations for use in conditioning regimens for stem cell transplant in autoimmune diseases. Autologous HSCT is to re-infuse immature cells that can re-establish blood production and patient's immune system.&#xD;
Cyclophosphamide: Alkylating agent which causes prevention of cell division by forming adducts with DNA Mesna: Medication used to decrease the risk of hemorrhagic cystitis rATG: lymphocyte-specific immunosuppressive agent Methylprednisolone: Steroid G-CSF: Granulocyte-colony stimulating factor; a glycoprotein that stimulates the bone marrow to produce granulocytes and stem cells and release them into the bloodstream Rituxan: Chimeric monoclonal antibody</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Non Treatment Related Death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Kathleen Quigley</name_or_title>
      <organization>Northwestern University</organization>
      <phone>312-695-8192</phone>
      <email>k-quigley@northwestern.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

